![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
K Beaumont, MA Kenney, AA Young and TJ Rink
Amylin Pharmaceuticals, Inc., San Diego, California 92121.
Amylin, a 37-amino acid peptide structurally related to calcitonin gene- related peptide, is synthesized in and released along with insulin from pancreatic beta-cells. Amylin is proposed to act as an endocrine partner to insulin, in part through actions upon skeletal muscle that promote cycling of gluconeogenic precursors to liver. We report here that binding sites with high affinity (Kd = 27 pm) for radioiodinated rat amylin are present in the nucleus accumbens region of rat brain. Competition experiments show that sites measured in nucleus accumbens membranes have high affinity for rat amylin, lower affinity for rat calcitonin gene-related peptides, and very low affinity for rat calcitonin. In contrast to rat calcitonin, salmon calcitonin has a high affinity for these sites, indicating that it shares critical binding determinants with amylin. We further tested whether salmon calcitonin shares with amylin the ability to regulate glycogen metabolism in rat skeletal muscle. Salmon calcitonin potently inhibits insulin-stimulated glucose incorporation into rat soleus muscle glycogen, suggesting that rat skeletal muscle may also contain receptor populations that have high affinity for both amylin and salmon calcitonin.
This article has been cited by other articles:
|
|
 |
|
  N. T. Bello, M. H. Kemm, and T. H. Moran Salmon calcitonin reduces food intake through changes in meal sizes in male rhesus monkeys Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2008; 295(1): R76 - R81. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. V. Edelman Optimizing Diabetes Treatment Using an Amylin Analogue The Diabetes Educator, January 1, 2008; 34(1_suppl): 4S - 10S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Aronne, K. Fujioka, V. Aroda, K. Chen, A. Halseth, N. C. Kesty, C. Burns, C. W. Lush, and C. Weyer Progressive Reduction in Body Weight after Treatment with the Amylin Analog Pramlintide in Obese Subjects: A Phase 2, Randomized, Placebo-Controlled, Dose-Escalation Study J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2977 - 2983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Smith, J. E. Blundell, C. Burns, C. Ellero, B. E. Schroeder, N. C. Kesty, K. S. Chen, A. E. Halseth, C. W. Lush, and C. Weyer Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study Am J Physiol Endocrinol Metab, August 1, 2007; 293(2): E620 - E627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. Kruger, C. L. Martin, and C. E. Sadler New insights into glucose regulation. The Diabetes Educator, March 1, 2006; 32(2): 221 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Schmitz, B. Brock, and J. Rungby Amylin Agonists: A Novel Approach in the Treatment of Diabetes Diabetes, December 1, 2004; 53(suppl_3): S233 - S238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Hull, G. T. Westermark, P. Westermark, and S. E. Kahn Islet Amyloid: A Critical Entity in the Pathogenesis of Type 2 Diabetes J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3629 - 3643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Aronoff, K. Berkowitz, B. Shreiner, and L. Want Glucose Metabolism and Regulation: Beyond Insulin and Glucagon Diabetes Spectr, July 1, 2004; 17(3): 183 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L Kleppinger and E. M Vivian Pramlintide for the Treatment of Diabetes Mellitus Ann. Pharmacother., July 1, 2003; 37(7): 1082 - 1089. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Buse, C. Weyer, and D. G. Maggs Amylin Replacement With Pramlintide in Type 1 and Type 2 Diabetes: A Physiological Approach to Overcome Barriers With Insulin Therapy Clin. Diabetes, July 1, 2002; 20(3): 137 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Poyner, P. M. Sexton, I. Marshall, D. M. Smith, R. Quirion, W. Born, R. Muff, J. A. Fischer, and S. M. Foord International Union of Pharmacology. XXXII. The Mammalian Calcitonin Gene-Related Peptides, Adrenomedullin, Amylin, and Calcitonin Receptors Pharmacol. Rev., June 1, 2002; 54(2): 233 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Lutz, S. Tschudy, A. Mollet, N. Geary, and E. Scharrer Dopamine D2 receptors mediate amylin's acute satiety effect Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2001; 280(6): R1697 - R1703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Tilakaratne, G. Christopoulos, E. T. Zumpe, S. M. Foord, and P. M. Sexton Amylin Receptor Phenotypes Derived from Human Calcitonin Receptor/RAMP Coexpression Exhibit Pharmacological Differences Dependent on Receptor Isoform and Host Cell Environment J. Pharmacol. Exp. Ther., July 1, 2000; 294(1): 61 - 72. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Samsom, L. A. Szarka, M. Camilleri, A. Vella, A. R. Zinsmeister, and R. A. Rizza Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition Am J Physiol Gastrointest Liver Physiol, June 1, 2000; 278(6): G946 - G951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Christopoulos, K. J. Perry, M. Morfis, N. Tilakaratne, Y. Gao, N. J. Fraser, M. J. Main, S. M. Foord, and P. M. Sexton Multiple Amylin Receptors Arise from Receptor Activity-Modifying Protein Interaction with the Calcitonin Receptor Gene Product Mol. Pharmacol., July 1, 1999; 56(1): 235 - 242. [Abstract] [Full Text]
|
|
|
|
|
|
T. A. Lutz, J. Althaus, R. Rossi, and E. Scharrer Anorectic effect of amylin is not transmitted by capsaicin-sensitive nerve fibers Am J Physiol Regulatory Integrative Comp Physiol, June 1, 1998; 274(6): R1777 - R1782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Y. Chai, G. Christopoulos, M. E. Cooper, and P. M. Sexton Characterization of binding sites for amylin, calcitonin, and CGRP in primate kidney Am J Physiol Renal Physiol, January 1, 1998; 274(1): F51 - F62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-J. Chen, S. Armour, J. Way, G. Chen, C. Watson, P. Irving, J. Cobb, S. Kadwell, K. Beaumont, T. Rimele, et al. Expression Cloning and Receptor Pharmacology of Human Calcitonin Receptors from MCF-7 Cells and Their Relationship to Amylin Receptors Mol. Pharmacol., December 1, 1997; 52(6): 1164 - 1175. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. J. Perry, M. Quiza, D. E. Myers, M. Morfis, G. Christopoulos, and P. M. Sexton Characterization of Amylin and Calcitonin Receptor Binding in the Mouse {alpha}-Thyroid-Stimulating Hormone Thyrotroph Cell Line Endocrinology, August 1, 1997; 138(8): 3486 - 3496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-F. Shyu, D. Inoue, R. Baron, and W. C. Horne The Deletion of 14Amino Acids in the Seventh Transmembrane Domain of a Naturally Occurring Calcitonin Receptor Isoform Alters Ligand Binding and Selectively Abolishes Coupling to Phospholipase C J. Biol. Chem., December 6, 1996; 271(49): 31127 - 31134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Cooper, P. G. McNally, P. A. Phillips, and C. I. Johnston Amylin Stimulates Plasma Renin Concentration in Humans Hypertension, September 1, 1995; 26(3): 460 - 464. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
